Antidiabetic treatment in patients aged >75 years with regular vs analog insulin (follow-up)
| HI/NPH n=1984 | BIA n=1852 | P value | |
| Insulin treatment strategy, % | |||
| BOT | 14.4 | 42.6 | <0.001 |
| CT | 56.2 | 13.2 | <0.001 |
| ICT | 29.4 | 44.3 | <0.001 |
| Rapid-acting insulin, % | 79.4 | 53.5 | <0.001 |
| Human | 61.3 | 19.3 | <0.001 |
| Analogs | 18.1 | 34.1 | <0.001 |
| Non-insulin antidiabetic treatment, % | |||
| Metformin | 23.3 | 28.7 | <0.001 |
| Sulfonylurea | 10.8 | 11.2 | 1.000 |
| Glucosidase inhibitors | 0.8 | 0.9 | 1.000 |
| Glinides | 3.7 | 6.1 | 0.002 |
| DPP-4 inhibitor | 10.0 | 25.8 | <0.001 |
| GLP-1 agonist | 0.8 | 2.2 | 0.001 |
| SGLT-2 inhibitor | 0.6 | 3.6 | <0.001 |
CT: prandial and basal insulin combined (up to 3 injection time points); ICT: prandial and basal insulin combined (>3 injection time points).
Bold numbers indicate p-values <0.05.
BIA, basal insulin analog; BOT, basal insulin-supported oral therapy: basal insulin only; CT, conventional insulin therapy; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HI, human insulin; ICT, intensified conventional insulin therapy; NPH, neutral protamine Hagedorn; SGLT-2, sodium/glucose cotransporter 2.